Elutia Inc. (ELUT) - Total Liabilities
Based on the latest financial reports, Elutia Inc. (ELUT) has total liabilities worth $34.68 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Elutia Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how Elutia Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Elutia Inc. short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Elutia Inc. Competitors by Total Liabilities
The table below lists competitors of Elutia Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Greattown Holdings Ltd B
SHG:900940
|
China | $5.57 Billion |
|
MClean Technologies Bhd
KLSE:0167
|
Malaysia | RM34.49 Million |
|
Abocom Systems Inc
TW:2444
|
Taiwan | NT$1.03 Billion |
|
QT Imaging Holdings, Inc. Common Stock
NASDAQ:QTI
|
USA | $16.58 Million |
|
Gamehaus Holdings Inc. Class A Ordinary Shares
NASDAQ:GMHS
|
USA | $15.93 Million |
|
Better Life Group Co Ltd
TW:1805
|
Taiwan | NT$352.66 Million |
|
BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877-
F:BLH
|
Germany | €1.05 Billion |
|
Buima Group
TWO:5543
|
Taiwan | NT$2.48 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Elutia Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Elutia Inc. worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Elutia Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Elutia Inc. (2018–2025)
The table below shows the annual total liabilities of Elutia Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $34.68 Million | -57.91% |
| 2024-12-31 | $82.39 Million | +0.44% |
| 2023-12-31 | $82.03 Million | +11.04% |
| 2022-12-31 | $73.87 Million | +37.70% |
| 2021-12-31 | $53.65 Million | -13.44% |
| 2020-12-31 | $61.98 Million | -37.95% |
| 2019-12-31 | $99.88 Million | +9.58% |
| 2018-12-31 | $91.15 Million | -- |
About Elutia Inc.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDer… Read more